| __timestamp | Halozyme Therapeutics, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 52602000 | 105558000 |
| Thursday, January 1, 2015 | 105812000 | 167094000 |
| Friday, January 1, 2016 | 113485000 | 212608000 |
| Sunday, January 1, 2017 | 285461000 | 285920000 |
| Monday, January 1, 2018 | 141726000 | 322725000 |
| Tuesday, January 1, 2019 | 150446000 | 256174000 |
| Wednesday, January 1, 2020 | 224227000 | 208904000 |
| Friday, January 1, 2021 | 361897000 | 215332000 |
| Saturday, January 1, 2022 | 520812000 | 219525000 |
| Sunday, January 1, 2023 | 636892000 | 266843000 |
| Monday, January 1, 2024 | 855907000 |
Cracking the code
In the dynamic world of biotechnology, financial performance often reflects a company's innovation and market adaptation. From 2014 to 2023, Halozyme Therapeutics, Inc. and MiMedx Group, Inc. have showcased intriguing trajectories in their gross profit margins. Halozyme's gross profit surged by over 1,100%, starting from a modest $52 million in 2014 to an impressive $637 million in 2023. This growth underscores Halozyme's strategic advancements and market penetration.
Conversely, MiMedx Group, Inc. experienced a more stable yet significant growth, with gross profits increasing by approximately 150% over the same period. Their peak in 2018, with a gross profit of $322 million, highlights a pivotal year of success. This comparative analysis not only highlights the resilience and adaptability of these companies but also offers insights into the broader biotech industry's evolving landscape.
Who Generates Higher Gross Profit? AstraZeneca PLC or MiMedx Group, Inc.
Gross Profit Trends Compared: Novartis AG vs Halozyme Therapeutics, Inc.
Gross Profit Trends Compared: Sanofi vs Halozyme Therapeutics, Inc.
Bio-Techne Corporation and Halozyme Therapeutics, Inc.: A Detailed Gross Profit Analysis
Catalent, Inc. and MiMedx Group, Inc.: A Detailed Gross Profit Analysis
Ascendis Pharma A/S vs Halozyme Therapeutics, Inc.: A Gross Profit Performance Breakdown
Gross Profit Trends Compared: Halozyme Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MiMedx Group, Inc.
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Gross Profit Comparison: MorphoSys AG and MiMedx Group, Inc. Trends
Gross Profit Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and MiMedx Group, Inc.